Breaking NewsLSE Cannabis Debutant Company MGC Pharma Set ‘To Break...

LSE Cannabis Debutant Company MGC Pharma Set ‘To Break Even This Year’

-

THE London Stock Exchange’s medical cannabis debutant MGC Pharmaceuticals has released is first quarterly update since listing showing record revenues of almost £500,000.

In the market update for the quarter up to March 31, it announced it has signed a supply deal to provide nutraceuticals producer and distributor Swiss PharmaCan a minimum of 40,000 units, per quarter, of its Covid-19 alleviating drug ArtemiC.

It reported progress on a number of trial initiatives including the launch of an in-vitro study into the treatment of aggressive glioblastoma brain cancer.

Roby Zomer, CEO of MGC Pharma, said: “This has been an historic quarter for MGC Pharma, following our listing on LSE, along with record sales for our proprietary pharmaceutical products. 

“MGC Pharma is well positioned for the future, with clinical trials for CannEpil and CogniCann due to begin in the coming quarter, alongside phase III clinical trials for CimetrA, which have the potential to treat the many people suffering as a result of Covid-19.

“MGC Pharma is now in an excellent position to realise its potential and build on the foundations that have been set in the past 12 months, as we remain on target to reach break even this financial year.”

MGC Pharma is dual-listed on both the Australian Securities Exchange and the LSE and valued at around £80m.


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are leading the fight against over-zealous German law enforcement in a...

UK CBD Consumption To Switch From Oils To Capsules – As New Research Estimates Market Value At £690m

CAPSULES are set to replace oils as the preferred method of CBD consumption - as new research show the...

Crowdfunding: An Emerging Capital Greenhouse For The Cannabis Industry

ALPHAGREEN is expected to hit close to the £2m crowdfunding mark on the Seedrs platform by mid-May – double...

Former JP Morgan Banker Lands Two UK Cannabis Jobs

A VETRAN of American investment bank JP Morgan has entered the burgeoning field of cannabis with appointments to two...

Europe’s Hemp Pioneer Posts Record Results With CBD, Construction And Car-Making To The Fore

EUROPEAN pioneer HempFlax has posted record annual results with revenues up 43% to €14.5m (£12.5m) as it returned a...

Sales Up Sharply At Sativa Wellness But Operational Costs Lead to £4.5m Loss

BRITISH CBD firm Sativa Wellness saw annual sales rise by over one-third in an eventful year which saw it...

Must read

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are...

You might also likeRELATED
Recommended to you